Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - APH LN

14 Jan 2025 15:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,312,879

2.28%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

12,312,879

2.28%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

1,100,000

61.15p

1p ordinary

Purchase

3,800,000

61.1p

1p ordinary

Purchase

1,200,000

61.15p

1p ordinary

Purchase

1,800,000

61.1p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

14 January 2024

Contact name:

James Evans

Telephone number:

+44 203 161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114766379/en/

Copyright Business Wire 2025

Date   Source Headline
21st Aug 20158:45 amRNSExercise of Share Options
17th Aug 20157:00 amRNSNotification of Interim Results
13th Jul 20157:00 amRNSPre-Close Trading Update
10th Jul 20157:00 amRNSAppointment of Finance Director
23rd Jun 20151:30 pmRNSDirector Shareholding
17th Jun 20155:30 pmRNSDirector Shareholding
1st Jun 20153:30 pmRNSExercise of Share Options
27th May 20152:00 pmRNSShare Options
27th May 20157:00 amRNSAGM Statement
20th Apr 20157:00 amRNSHardman & Co issues research report
15th Apr 20157:00 amRNSExercise of Share Options
10th Apr 20157:00 amRNSAnnual Report and AGM Notice
25th Mar 20157:00 amRNSPreliminary Results
3rd Mar 20159:30 amRNSExercise of Share Options
17th Feb 20157:00 amRNSDirectorate Change
16th Feb 20157:00 amRNSNotification of Preliminary Results
2nd Feb 201512:15 pmRNSAcquisition of MacuVision
26th Jan 20157:00 amRNSAppointment of Non-Executive Director
19th Jan 20157:00 amRNSPre-Close Trading Update
18th Dec 20143:27 pmRNSDirectorate Change
10th Sep 20147:00 amRNSAlliance Pharma PLC Interim Results
5th Aug 20147:00 amRNSNotification of Interim Results
9th Jul 20147:00 amRNSPre-Close Trading Update
19th Jun 20145:35 pmRNSExercise of Share Options
21st May 20147:00 amRNSAGM Statement
11th Apr 20142:30 pmRNSShare Options
11th Apr 20147:00 amRNSMajor Interest in Shares
10th Apr 20142:57 pmRNSExercise of Share Options
10th Apr 20147:00 amRNSAnnual Report and Notice of AGM
7th Apr 20142:45 pmRNSTR-1: Notification of Major Interest in Shares
1st Apr 20147:00 amRNSAppointment of Non-Executive Director
26th Mar 20147:00 amRNSPreliminary Results
4th Feb 20147:00 amRNSNotification of Preliminary Results
23rd Jan 20149:30 amRNSTR-1: Notification of Major Interest in Shares
20th Jan 20147:00 amRNSDirector Shareholding
14th Jan 20147:00 amRNSAcquisition in Germany
14th Jan 20147:00 amRNSPre-Close Trading Update
30th Dec 20132:00 pmRNSDirectorate Change
19th Dec 20132:45 pmRNSCULS Conversion and Additional Listing
18th Dec 20137:00 amRNSAcquisition of Lypsyl
9th Dec 20137:00 amRNSMajor Interest in Shares
2nd Dec 20136:00 pmRNSCULS Conversion and Additional Listing
11th Nov 20134:20 pmRNSCULS Conversion and Additional Listing
7th Nov 20131:46 pmRNSCompulsory Conversion of CULS
28th Oct 20133:01 pmRNSCULS Conversion and Additional Listing
25th Oct 20138:00 amRNSMajor Interest in Shares
24th Oct 20135:55 pmRNSShare Options
22nd Oct 20139:30 amRNSCULS Conversion and Additional Listing
11th Oct 20137:00 amRNS£55 Million Bank Facilities
16th Sep 20132:01 pmRNSCULS Conversion and Additional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.